Morgan Stanley Exceeds Expectations with Strong Earnings Growth
Financial Performance and Analyst Insights
Morgan Stanley (MS), an investment bank and financial services firm based in New York, boasts a market capitalization of $221 billion. The company provides a wide array of services such as investment banking, wealth management, and asset management. It is especially well-regarded for its expertise in mergers and acquisitions (M&A) advisory and capital raising for corporations, governments, and individual investors.
Over the past year, Morgan Stanley’s stock has significantly outperformed the broader market. Shares have surged by 56.7% in this timeframe and increased by 8.8% in 2025 thus far. For context, the S&P 500 Index ($SPX) has gained 21.8% over the past year and just 2.7% year-to-date.
In comparison to the SPDR S&P Capital Markets ETF (KCE), which rose 42% over the past year and 4.6% in 2025, Morgan Stanley has clearly shown its strength.
On January 16, MS shares experienced a 4% jump following the release of its fourth-quarter and fiscal 2024 earnings report. The firm reported a record-high annual revenue of $61.8 billion, with investment banking revenue climbing 35% thanks to strong M&A activity and stock sales. This momentum positions Morgan Stanley for continuous growth in 2025, backed by its largest M&A pipeline in seven years.
Analysts project that, for the fiscal year ending December 2025, Morgan Stanley’s adjusted earnings per share (EPS) will increase by 7.2% compared to last year, reaching $8.52. Notably, the company has maintained a history of surpassing Wall Street earnings estimates in the last four quarters.
Currently, MS stock holds a consensus rating of “Moderate Buy.” Among the 23 analysts covering the stock, six have a “Strong Buy” recommendation, one has a “Moderate Buy,” and 16 suggest a “Hold.”
This analyst consensus has remained fairly stable over recent months.
On January 20, UBS Group AG (UBS) raised its price target for Morgan Stanley to $140 from $130, while keeping a “Neutral” rating. UBS noted the strength of both the Wealth Management and Investment Banking divisions, highlighting stabilized net interest income and a more favorable environment for initial public offerings (IPOs). While there was a slowdown in net new asset growth in Q4, UBS anticipates a rebound, supported by robust loan growth and positive trends from Morgan Stanley’s stock plan business.
The mean price target for Morgan Stanley’s stock stands at $138.95, indicating a potential upside of 1.6% from current levels. Meanwhile, the highest target of $156 suggests a premium of 14% over the current share price.
On the date of publication, Kritika Sarmah did not hold (either directly or indirectly) any positions in any of the securities mentioned in this article. The information in this article is for informational purposes only. For further details, please refer to the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
